Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Cariprazine – Novel Antipsychotic for the Treatment of Schizophrenia

V.E. Medvedev

RUDN University, Moscow, Russia

Summary. Cariprazine is a novel antipsychotic, partial agonist of D3/D2 dopamine receptors with predominantly action on D3 receptors. High efficacy in treatment of schizophrenia including that with predominant negative symptoms and good tolerability of cariprazine were established in several randomized controlled trials. Cariprazine doesn’t impair metabolism, doesn’t have an impact on QT interval, doesn’t cause prolactin elevation. The drug can be used in treatment of adult patients with schizophrenia with positive and negative symptoms including those with high risk of metabolic and cardiovascular complications.

Contact: medvedev_ve@rudn.ru

References: 

1. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 // Lancet. – 2013. – Vol. 382 (9904). – P. 1575–1586.

2. Fleischhacker W.W., Arango, C., Arteel, P., Barnes, T.R., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S.R., Moller, M., Sartorius, N., Woodruff, P. Schizophrenia—time to commit to policy change // Schizophr Bull. – 2014. – Vol. 40, Suppl. 3. – P. 165–194.

3. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl, J. American Psychiatric Steering Committee on Practice. Practice guideline for the treatment of patients with schizophrenia, second edition // Am J Psychiatry. – 2004. – Vol. 161, Suppl. 2. – P. 1–56.

4. Olivares J.M., Sermon J., Hemels M., Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review // Ann General Psychiatry. – 2013. –Vol. 12 (1). –P. 32.

5. Karlson A., Lekrub`e I. Dofaminovaya teoriya patogeneza shizofrenii: rukovodstvo dlya vrachej. – London: Taylor & Francis, 2004.

6. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia // Annu Rev Med. – 2001. – Vol. 52. – P. 503–517.

7. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs // Mol Psychiatry. – 2005. – Vol. 10. – P. 79–104.

8. Stahl S.M. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. – 3nd ed. – Cambridge: Cambridge University Press, 2008. – 1117 p.

9. Matsui M., Sumiyoshi T., Arai H. et al. Cognitive functioning related to quality of life in schizophrenia // Prog Neuropsychopharmacol Biol Psychiatry. – 2008. – Vol 32. –P. 280–287.

10. Savilla K., Kettler L., Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia // Aust N Z J Psychiatry. – 2008. – Vol. 42. – P. 496–504.

11. Blanchard J.J., Kring A.M., Horan W.P. et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia // Schizophr Bull. – 2011. – Vol. 37. – P. 291–299.

12. Mosolov S.N. Nekotory`e aktual`ny`e teoreticheskie problemy` diagnostiki, klassifikacii, nejrobiologii i terapii shizofrenii: sravnenie zarubezhnogo i otechestvennogo podxodov // Zhurnal nevrologii i psixiatrii imeni C.C. Korsakova. – 2010. – T. 110, № 6. – S. 4–11.

13. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials // Schizophr Bull. – 2011. –Vol. 37. – P. 255–256.

14. European Medicines Agency. Guideline on clinical investigation of medicinal products, including depot preparation in the treatment of schizophrenia. 20 September 2012; EMA/CHMP/40072/2010 Rev. 1. Committee for Medicinal Products for Human Use (CHMP). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin... (accessed Dec 4, 2015).

15. Mosolov S.N., Czukarzi E`.E`., Kapiletti S.G. Antipsixoticheskaya farmakoterapiya shizofrenii: ot nauchny`x danny`x k klinicheskim rekomendaciyam // Biologicheskie metody` terapii psixicheskix rasstrojstv. Dokazatel`naya medicina – klinicheskoj praktike / pod red. S.N. Mosolova. – M.: Social`no-politicheskaya my`sl`, 2012. – S. 11–61.

16. Medvedev V.E`. Lechenie shizofrenii sovremenny`mi atipichny`mi antipsixoticheskimi preparatami: uchebno-metodich. posobie. – M.: OAO «Konti-Print», 2014. – 72 s.

17. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors // Prog Neuropsychopharmacol Biol Psychiatry. – 2003. – Vol. 27. – P. 1081–1090.

18. Mosolov S.N., Czukarzi E`.E`. Psixofarmakoterapiya shizofrenii // Psixiatriya: nacional`noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: Izdatel`skaya gruppa «GE`OTAR-Media», 2018. – S. 299–328.

19. Lieberman J.A., Phillips M., Gu H. et al. Atypical and conventional antipsychotic drugs in treatment – naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine // Neuropsychopharmacology. – 2003. – Vol. 28. – P. 995–1003.

20. Kapur S., Zipursky R., Jones C. et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double–blind PET study of first–episode schizophrenia // Amer J Psychiatry. – 2000. – Vol. 157. – P. 514–520.

21. Kapur S., Zipursky R., Jones C. et al. Positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy // Arch Gen Psychiatry. – 2000. – Vol. 57 (6). – P. 553–559.

22. Sebastian C.S., Glazer W., Buckley P.F. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia // Curr Med Chem. – 2004. – Vol. 11. – P. 329–342.

23. Cho D.I., Zheng M., Kim K.M. Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors // Arch Pharm Res. – 2010. – Vol. 33. – P. 1521–1538.

24. Gross G., Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions // Handb Exp Pharmacol. – 2012. – Vol. 213. – P. 167–210.

25. Mosolov S.N., Alfimov P.V. Rol` dofaminovy`x D3-receptorov v mexanizme dejstviya sovremenny`x antipsixotikov // Sovremennaya terapiya psixicheskix rasstrojstv. – 2014. – № 1. – S. 2–9.

26. Schwartz J.C., Diaz J., Pilon C. et al. Possible implications of the dopamine D (3) receptor in schizophrenia and in antipsychotic drug actions // Brain Res Brain Res Rev. – 2000. – Vol. 31. – P. 277–287.

27. Gyertyán I., Sághy K., Laszy J. et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15 // Naunyn Schmiedebergs Arch Pharmacol. – 2008. – Vol. 378. – P. 529–539.

28. Kiss B., Horváth A., Némethy Z., et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile // J Pharmacol Exp Ther. – 2010. – Vol. 333. – P. 328–340.

29. Morozov P.V., Medvedev V.E`. Kariprazin – novy`j antipsixotik dlya lecheniya e`ndogenny`x psixicheskix rasstrojstv // Psixiatriya i psixofarmakoterapiya imeni P.B. Gannushkina. – 2014. – № 1. – S. 9–14.

30. Shmukler A.B. Kariprazin – antipsixotik s novy`mi unikal`ny`mi potencial`ny`mi vozmozhnostyami dlya lecheniya shizofrenii i affektivny`x rasstrojstv // Social`naya i klinicheskaya psixiatriya. – 2014. – № 24 (2). – S. 72–75.

31. Durgam S., Greenberg W.M., Li D. et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study // Psychopharmacology (Berl). – 2017. –Vol. 234 (2). – P. 199–209.

32. Keator D.B., Mukherjee J., Preda A., et al. Dopamine D2 and D3 receptor occupancy of cariprazine in schizophrenic patients // Schizophr Bull. – 2009. – Vol. 35, Suppl. 1. – P. 154.

33. Potkin S., Keator D., Mukherjee J. et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients // Eur Neuropsychopharmacol. – 2009. – Vol. 19, Suppl. 3. – P. 316.

34. Zimnisky R., Chang G., Gyertyán I., Kiss B. et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse // Psychopharmacology (Berl). – 2013. – Vol. 226 (1). – P. 91–100.

35. Choi Y.K., Adham N., Kiss B. et al. Long-term effects of cariprazine exposure on dopamine receptor subtypes // CNS Spectr. – 2014. – Vol. 19 (3). – P. 268–277.

36. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives // Curr Opin Investig Drugs. – 2010. –Vol. 11. – P. 802–812.

37. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: Adv Ther (2013) Page 13 of 13 rationale and perspectives // Curr Opin Investig Drugs. – 2010. – Vol. 11. – P. 802–812.

38. Werner F.M., Coveñas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine // Ther Clin Risk Manag. – 2015. – Vol. 11. – P. 1657–1661.

39. Pásztor Mészáros G., Agai-Csongor E., Kapaś M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine // J Pharm Biomed Anal. – 2008. – Vol. 48 (2). – P. 388–397.

40. Meszaros G.P., Kapas M., Borsos M., et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects // Eur Neuropsychopharmacol. – 2007. – Vol. 217, Suppl. 4. – P. 451–452.

41. Kapas M., Meszaros G.P., Yu.B. et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers // Eur Neuropsychopharmacol. – 2008. – Vol. 18, Suppl. 4. – P. 433.

42. Stahl S.M. Case Studies: Stahl’s Essential Psychopharmacology: Vol. 2. – 1st ed. – Cambridge: Cambridge University Press, 2017.

43. Kirschner N., Gemesi L.I., Vastag M. et al. In vitro metabolism of RGH-188 // Drug Metab Rev. – 2008. – Vol. 40, Suppl. 1. – P. 128–129.

44. Kapas M., Meszaros G.P., Yu B. et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers // Eur Neuropsychopharmacol. – 2008. – Vol. 18, Suppl. 4. –P. 433.

45. Durgam S., Bose A., Starace A. et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial // Schizophr Res. – 2014. – Vol. 152. – P. 450–457.

46. Lieberman J.A., Cutler A.J., Wan S. et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial // Eur Neuropsychopharmacol. – 2013. – Vol. 23, Suppl. 2. – P. 477–478.

47. Litman R., Papadakis K., Durgam S., Xie J. Use of cariprazine in the treatment of schizophrenia: a proofof-concept trial // Poster Presentation 61, 60th Institute on Psychiatric Services of the American Psychiatric Association. Chicago, IL, 2–5 Oct 2008. – Chicago, 2008.

48. Zukin S., Kane J., Cutler A.J. et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: A phase III, international, randomized, double-blind, placebo-controlled trial // Neuropsychopharmacol. – 2012. –Vol. 38. – P. 319.

49. Cutler A.J., Mokliatchouk O., Laszlovszky I. et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose phase III, randomized, double-blind, placebo- and active-controlled trial // APA Abstract Book. 166th Annual Meeting of the American Psychiatric Association. San Francisco, CA, 18–22 May 2013. – San Francisco, 2013. – P. 210.

50. Citrome L. Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy // Adv Ther. – 2013. – Published online: January 28. DOI: 10.1007/s12325-013-0006-7

51. Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. Results From an International, Phase III Clinical Trial // J Clin Psychopharmacol. – 2015. – Vol. 35. – P. 367–373.

52. Citrome L., Durgam S., Lu K. et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials // J Clin Psychiatry. – 2016. – Vol. 77 (1). – P. 109–115.

53. Earley W., Durgam S., Lu K. et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies // Int Clin Psychopharmacol. – 2017. – Vol. 32 (6). – P. 319–328.

54. Zhao M.J., Qin B., Wang J.B. et al. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials // J Clin Psychopharmacol. – 2018. – Vol. 38 (1). – P. 55–59.

55. Németh G., Laszlovszky I., Czobor P. et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial // Lancet. – 2017. – Vol. 389 (10074). – P. 1103–1113. Available at: http://dx.doi.org/10.1016/S0140-6736(17)30060-0 (accessed May 27, 2019).

56. Kane J.M. Treatment strategies to prevent relapse and encourage remission // J Clin Psychiatry. – 2007. – Vol. 68, Suppl. 14. – P. 27–30.

57. S., Earley W., Li R. et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial // Schizophrenia Research. – 2016. – Vol. 176. – P. 264–271.

58. Németh B., Molnár A., Akehurst R. et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone // J Comp Eff Res. – 2017. – Vol. 6 (8). – P. 639–648.

59. Krause M., Zhu Y., Huhn M. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis // Eur Arch Psychiatry Clin Neurosci. – 2018. – Vol. 268 (7). – P. 625–639.

60. Ketter T.A., Sachs G.S., Lu K. et al. Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder // APA Abstract Book, 166th Annual Meeting of the American Psychiatric Association. 18–22 May 2013, San Francisco, CA. – San Francisco, 2013. – P. 163–164.

61. Bose A., Li D., Migliore R. et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia // Poster Presentation I-73, NCDEU 50th Annual Meeting. Boca Raton, FL, 14–17 June 2010. – Boca Raton, 2010.

62. Nasrallah H.A., Earley W., Cutler A.J. et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis // BMC Psychiatry. – 2017. – Vol. 17 (1). – P. 305.

63. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications // Can J Psychiatry. – 2006. – Vol. 51. – P. 480–491.